Introduction

Non-infectious uveitis refers to a group of pathologies characterized by various etiologies which are frequently difficult to determine explicitly. Local and systemic glucocorticosteroids (GC) are still the basic treatment. However, due to their ineffectiveness in some patients immunosuppressive drugs need to

Abstract:

Aim: The aim of the study involved the assessment of long-term effectiveness of mycophenolate mofetil treatment in patients with chronic non-infectious uveitis.

Material and Methods: A retrospective analysis included case histories of 19 patients receiving mycophenolate mofetil with a follow-up period of at least 36 months. We assessed the possibility of reducing the dose of prednisolone to a dose equal to or lower than 10 mg daily and achieving a remission after mycophenolate mofetil discontinuation. Moreover, the change in the best corrected visual acuity was evaluated at baseline and at the end of the follow-up.

Results: Nineteen patients were included in the study. The majority of them were women (18/19; 95%). The average age when immunosuppressive therapy was introduced was 44 years (ranging from 21 to 75 years). The therapeutic success of glucocorticosteroid reduction, defined as the absence of symptoms of inflammation at the dose of prednisolone equal to or lower than 10 mg per day, recorded during at least two follow-up visits planned 28 days apart after one year of therapy was obtained in 13 out of 16 patients (81%), and after two years – in 14 out of 16 patients (87%). After the completion of the therapy the recurrence was noted in 7 patients on average after a year. The total of 20 out of 31 eyes (64%) achieved vision stabilization, an improvement occurred in eight eyes (26%) and deterioration in three (10%).

Conclusions: Data obtained from this study confirm the long-term effectiveness of mycophenolate mofetil in the treatment of non-infectious uveitis.

Key words: mycophenolate mofetil, non-infectious uveitis, immunosuppressive treatment

Introduction

Non-infectious uveitis refers to a group of pathologies characterized by various etiologies which are frequently difficult to

Czy korzystny efekt mykofenolanu mofetilu w leczeniu nieinfekcyjnych zapaleń błony naczyniowej utrzymuje się długoterminowo?

Maja Waszczyk-Łączak¹, Jacek P. Szaflik¹,²

¹ Independent Public University Ophthalmic Hospital of Warsaw, Poland
Head: Professor Jacek P. Szaflik, MD, PhD
² Department of Ophthalmology, 2nd Faculty of Medicine, the Medical University of Warsaw, Poland
Head: Professor Jacek P. Szaflik, MD, PhD

Abstract:

Cel: ocena długoterminowego efektu leczenia mykofenolanem mofetilu pacjentów z przewlekłym nieinfekcyjnym zapaleniem błony naczyniowej.

Materiał i metody: dokonano retrospektywnej analizy historii chorób 19 pacjentów otrzymujących mykofenolan mofetilu, u których okres obserwacji wynosił przynajmniej 36 miesięcy. Ocenição możliwość zredukowania dawki prednizolonu do dawki równnej 10 mg bądź mniejżej dziennie, a także uzyskanie remisji po odstawieniu mykofenolanu mofetilu. Analizowano również zmianę najlepszej skorygowanej ostrości wzroku na początku leczenia i na końcu obserwacji.

Wyniki: do badania włączono 19 pacjentów. Większość z nich stanowiły kobiety, aż 18 (95%). Średnia wieku podczas włączenia terapii immunosupresyjnej to 44 lata (zakres od 21 do 75 lat). Sukces terapeutyczny redukcji glikokortykosteroidów określono jako brak objawów zapalenia w warunkach stosowania dawki prednizolonu równej 10 mg bądź mniejżej dziennie, a także uzyskanie redukcji ostrości wzroku na przynajmniej dwóch wizytach kontrolnych oddzielonych 28 dniami przerwy, po roku terapii uzyskano go u 13 spośród 16 pacjentów (81%), po dwóch latach – u 14 spośród 16 pacjentów (87%). Po zakończeniu terapii u 7 osób zaznaczono poprawę w porównaniu do przerwy – średnio po roku. W 20 oczach (64%) spośród 31 oczu uzyskano stabilizację widzenia, poprawa wystąpiła w 8 oczach (26%), a pogorszenie w 3 oczach (10%).

Wnioski: uzyskane dane potwierdzają długotrwałą skuteczność mykofenolanu mofetilu w leczeniu nieinfekcyjnego zapalenia błony naczyniowej.

Słowa kluczowe: mykofenolan mofetil, nieinfekcyjne zapalenie błony naczyniowej, leczenie immunosupresyjne

Autorzy zgłaszają brak konfliktu interesów w związku z publikowaną pracą/ The authors declare no conflict of interest

https://doi.org/10.5114/ko.2019.84562
Does the beneficial effect of mycophenolate mofetil persist long-term in the treatment of non-infectious uveitis?

Material and Methods

A retrospective analysis of data included in 31 case histories was conducted. The study group patients were treated with mycophenolate mofetil for non-infectious uveitis at the clinic of Independent Public University Ophthalmic Hospital in Warsaw. 19 patients with a follow-up period of at least 36 months were qualified for the study.

Patients qualified for immunosuppressive treatment were recruited from a group of the most severe cases. They usually had had a history of several years of the disease with several recurrences of the inflammation. When MMF was introduced into the treatment most of the patients were receiving GCs. The criteria for inclusion were as follows: a diagnosis of chronic non-infectious uveitis, mycophenolate mofetil treatment and 36 months of documented follow-up. The exclusion criteria were the inflammation of eye tissue other than uveitis and a shorter follow-up period.

The regimen of mycophenolate mofetil treatment was determined individually for each patient. The dose depended on the type of uveitis and the general health of the patient comprising the body weight and concomitant systemic diseases. Initially, the majority of patients received 1000 mg of MMF twice a day and GCs. At first we aimed at the reduction of GC dose combined with a gradual reduction of MMF dose. Subsequently, MMF discontinuation was planned. If uveitis recurred during the process of dose reduction, the dose of the immunosuppressive drug was increased again. Since immunosuppressive therapy may activate viral infections (e.g. herpes simplex virus, cytomegalovirus, human papillomavirus) and induce atypical infections (Pneumocystis jirovecii, prophylaxis for 6 months with acyclovir (4 x 400 mg daily) and co-trimazole (480 mg twice daily for 3 months tapered to 480 mg daily) was introduced.

During the treatment we aimed at achieving the remission of uveitis manifestations while introducing the maximum reduction of GC dose (equal to or lower than 10 mg of prednisolone) and a complete MMF discontinuation. According to SUN Working Group guidelines the therapeutic success of GCs dose reduction was defined as the lack of inflammation manifestations at a dose of prednisolone equal to or lower than 10 mg daily (or an equivalent dose of methylprednisolone). The remission of inflammation after GC dose reduction had to be reported during at least two follow-up visits 28 days apart.

The remission was also determined using those guidelines according to which 3 asymptomatic months following MMF discontinuation was viewed as achieving therapeutic success. At baseline all the patients underwent a complete ophthalmological examination including best corrected visual acuity (BCVA), tonometry, the assessment of the anterior and posterior segment of the eye with the slit lamp. The classification of uveitis was performed on the basis of guidelines of the Standardization of Uveitis Nomenclature (SUN) Working Group.

The following information concerning the patients qualified for the study was obtained from their medical histories: demographic data, information about the duration of the disease and the number of recurrences prior to MMF introduction, previous immunosuppressive therapy, the reason for MMF introduction, drug dosages, disease complications, the frequency of surgical procedures, treatment duration, follow-up durations and the occurrence of inflammatory relapses during those periods, achieving the effectiveness of glucocorticosteroid dose reduction, successful remission obtained after MMF discontinuation, reason for MMF discontinuation, the occurrence of adverse effects and BCVA. The frequency of follow-up visits depended on the local status and the stage of treatment of a patient.

The aim of the study involved the assessment of the effectiveness of mycophenolate mofetil treatment in patients with chronic non-infectious uveitis. The follow-up period of at least 36 months was an inclusion criterion in this study.

Visual acuity was assessed during each follow-up visit with the Snellen chart. The values obtained during examination were changed in accordance with appropriate rules into logMAR units with the lowest: counting fingers in front of the patient’s eye – 1.9; hand motion in front of the patient’s eye – 2.3; light perception – 2.7; no light perception – 3.0. Improvement or deterioration in visual acuity was reported with a change of at least 0.3 logMAR which translates into three rows on the Snellen chart.

Follow-up visits involved taking a history concerning possible adverse effects of the therapy and the assessment of basic laboratory tests. The small size of the study group was the re-
ason why statistical formulas could not be used. Therefore, the calculations were executed with Excel spreadsheet.

The retrospective study was approved by the Bioethics Board of the Medical University of Warsaw.

Results

19 patients were included in the study. The majority of them were women (18/19; 95%). The average age when immunosuppressive therapy was introduced was 44 years (ranging from 21 to 75 years). Table I includes patient characteristics.

Patients qualified for immunosuppressive treatment were recruited from a group of the most severe cases. Over half of the patients had had at least 6 inflammatory episodes prior to MMF introduction and the average duration of the disease was 10 years.

The average duration of follow-up after MMF therapy initiation was 51 months, the longest one was 106 months with a minimum of 36 months being an inclusion criterion. One patient was also continued on cyclosporine for the first 10 months of mycophenolate mofetil treatment.

The therapeutic success was defined as the absence of symptoms of inflammation at the dose of prednisolone of ≤10 mg per day, recorded during at least two follow-up visits planned 28 days apart. Three patients did not receive GCs during MMF treatment. A yearly therapy proved successful in 13 out of 16 patients (81%), and two years of therapy – in 14 out of 16 patients (87%). Detailed data concerning GC dose reduction are included in Figure 1. Notably, some patients had the dose reduced to 10 mg during the first year, and then GC

| Patients characteristics/ Charakterystyka pacjentów | n | % |
|-----------------------------------------------------|---|---|
| Mean age/ Średnia wieku [years/lata]                | 44.3 (21–75) |
| % female/ % kobiet                                 | 18 | 95% |
| Unilateral uveitis (R/L)/ Choroba jednooczna (P/L) | 7(2/5) | 37% (11/26) |
| Bilateral uveitis/ Choroba obuocza                  | 12 | 63% |
| Uveitis type/ Typ zapalenia                         | | |
| Anterior uveitis/ Zapalenie przedniego odcinka błony naczyniowej | 6 | 32% |
| Intermediate uveitis/ Zapalenie części pośredniej błony naczyniowej | 3 | 16% |
| Posterior uveitis/ Zapalenie tylnego odcinka błony naczyniowej | 4 | 21% |
| Panuveitis / Zapalenie całej błony naczyniowej      | 6 | 32% |
| Mean duration of uveitis before MMF/ Średni czas trwania choroby przed włączeniem MMF [lata] | 10.3 |
| min [years]                                        | 0.1 |
| max [years]                                        | 31 |
| Number of episodes before MMF/ Liczba epizodów przed włączeniem immunosupresji | | |
| Less than 5 episodes/ Poniżej 5 epizodów            | 8 | 42% |
| 6–10 episodes/ Od 6 do 10 epizodów                  | 2 | 10% |
| More than 10 episodes/ Powyżej 10 epizodów         | 9 | 48% |
| Previous immunosuppressive treatment/ Wcześniesze leczenie immunosupresyjne | 7 | 37% |
| Azathiopryne                                        | 5 | 72% |
| Cyclosporyne A                                     | 1 | 14% |
| Methotrexate                                        | 1 | 14% |
| Reason for starting MMF treatment/ Powód włączenia MMF | | |
| Inefficacy of corticosteroid therapy/ Niepowodzenie terapii samymi steroidami | 8 |
| Dependence on steroids/ Steroidozależność           | 2 |
| Inefficacy of previous immunosuppressive therapy/ Brak skuteczności innych leków immunosupresyjnych | 5 |
| Other reason/ Inny powód                           | 4 |

Tab. I. Patient characteristics, uveitis and treatment.
Tab. I. Charakterystyka pacjentów, choroby i leczenia.
Does the beneficial effect of mycophenolate mofetil persist long-term in the treatment of non-infectious uveitis?

The dose was further reduced to 5 mg and even discontinued. At the beginning of MMF treatment 13 patients received prednisone at a dose higher than 10 mg daily (68%).

All the patients received MMF for the first 6 months. After a year the treatment was continued in 12 patients (63%), and after two years – in 4 patients (21%). The average baseline dose of MMF was 1763 mg, with 16 patients (84%) receiving 1500 mg or 2000 mg daily. The first dose reduction was done after the average of 4 months of treatment with 13 patients (68%) having the dose reduced during the first 3 months of treatment. Average doses during two years of follow-up are included in Figure 2. The increase at 18 months of treatment was associated with an increased MMF dose in two out of six patients. In one patient the change of dose was connected with perioperative cataract prophylaxis and in the other – to the occurrence of an inflammatory episode.

The average duration of treatment in the study group was 30 months (from 4 to 106 months). The average duration of follow-up after treatment was 21 months (from 0 to 42 months). The analysis of the causes of MMF discontinuation were as follows: 59% patients achieved a therapeutic success, in 10% the therapy was ineffective, 5% of patients had adverse effects, one patient (5%) failed to observe medical advice and made a personal decision to discontinue the drug. Four patients continued treatment with MMF at the moment of study completion.

During the treatment, inflammatory episodes occurred in eight patients (42%). Recurrences were the most common after GC dose reduction – 4 times, 3 episodes were reported with mycophenolate mofetil dose reduction and 3 others when both MMF and GCs were reduced. The average MMF dose at which the inflammatory process recurred was 875 mg, with as many as 5 patients (62.5%) receiving a 500 mg dose of immunosuppressive drug at that time. However, after completing the treatment the disease recurred in 7 patients – on average after a year. Interestingly, an inflammatory episode occurred in 5 patients over a 7-month period, while no recurrences were noted over a 3-month period. A remission criterion was met in all the patients after MMF discontinuation. Detailed data are included in Table II.

### Table II

| Recurrence of inflammation/Nawroty zapalenia | Data/ Dane |
|--------------------------------------------|------------|
| Patients with recurrences after dose reduction of MMF/Liczba osób, u których wystąpił nawrót po redukcji dawki MMF | 6 |
| The mean dose of MMF at which the uveitis recurred/Średnia dawka jakie podawano gdy wystąpił nawrót | 875 mg/day |
| How many patients then received 500mg/ day?/Ilu pacjentów otrzymywało wtedy 500 mg/dz? | 5 |
|Patients with recurrences after MMF discontinuation/Liczba osób, u których wystąpił nawrót po odstawieniu MMF | 7 |
| The average time after which the relapse occurred [month]/Po jakim czasie od odstawienia wystąpiła nawrót? [w miesiącach] | 11.7 |
| The number of patients whose relapse occurred after 7 months?/U ilu pacjentów nawrót wystąpił do 7. miesiąca? | 5 |
| Has the immunosuppressive drug been re-introduced?/Czy lek immunosupresyjny został ponownie włączony? | 3 |
| Which drug was re-introduced?/Jaki lek włączono ponownie? | MMF-2, MTX-1 |

Tab. II. Detailed data on recurrence of inflammation during the whole observation.

Tab. II. Szczegółowe dane dotyczące nawrotów zapalenia podczas całej obserwacji.
The most common ophthalmological complication occurring in the study group was cataract (15 patients, 79%), thus phacoemulsification was the dominant surgical procedure (13 surgeries). Data are included in Figures 3a and 3b.

Fig 3a., 3b. Complications and procedures during the follow-up period.

Ryc. 3a., 3b. Powikłania i wykonane procedury podczas okresu obserwacji.

A long-term effect of immunosuppressive treatment was assessed on the basis of the best corrected visual acuity. The following BCVA values were compared: at the beginning of MMF treatment and at the end of follow-up. In case of bilateral disease the BCVA was analyzed in the eye with the superior visual acuity. A total of 20 out of 31 eyes (64%) achieved vision stabilization, an improvement occurred in 8 eyes (26%) and deterioration in 3 (10%).

During mycophenolate mofetil treatment 5 patients (26%) experienced adverse effects and 2 of them required dose reduction. Hematologic abnormalities were the most common. The severity of adverse effects necessitated drug discontinuation in one patient. She experienced hematologic complications manifesting as ecchymoses and hematomas affecting the whole skin. Despite dose reduction the patient lost her consciousness and had to be hospitalized.

Discussion

The aim of the present involved a detailed assessment of non-infectious uveitis treated with mycophenolate mofetil with the follow-up period of at least 3 years. We also assessed to what extent the therapeutic success achieved at the beginning of the treatment continued over time and how commonly the disease recurred after mycophenolate mofetil discontinuation.

The majority of published research papers concerning the use of MMF in patients with uveitis involved a short follow-up period, usually limited to a year. Few researchers concentrated on the description of changes occurring after a period of 12 months. In the present paper therapeutic success, defined as the possibility of prednisone dose reduction to 10 mg and also inactivity of uveitis during the 12th month of the follow-up, was achieved by 81% of patients. Such a result is comparable with proportions obtained in other studies – from 72% (8), through 83.3% (9), 84.6% (2) to 86% (4) of patients. A certain aspect of GC dose reduction is worth noting. During long-term follow-up some patients achieved the aim over the first months of MMF treatment, but later, if the disease recurred, a dose increase was necessary. The present authors decided not to include graphically presented data which were prepared, because it would considerably impede the interpretation of the results.

The patients treated with mycophenolate mofetil at our clinic were initially administered a dose of 1000 mg twice daily in most cases, which correlates with treatment regimens implemented in other centers. However, professional literature provides scarce data referring to the continuation of MMF treatment in patients with uveitis. Teoh et al. reported that in their center the initial dose amounted to 2000 mg daily. In case of the ineffectiveness of treatment it was increased to 3000 mg daily and reduced to 1000 mg if good response was achieved. The authors did not specify the period during which the effectiveness was assessed (2). Chilean physicians implemented a slightly different strategy. They initiated the treatment on 500 mg twice daily and increased it later to 2000 mg administered in two doses. Treatment regimen was not described, but it may be indirectly inferred that high doses of MMF were administered over a long time. Two patients experienced serious complications (non-Hodgkin lymphoma and bronchoalveolar carcinoma) after a 38-month treatment with 2000 mg of MMF and after a 36-month treatment with 1500 mg of MMF daily. Siepmann et al. implemented a completely different regimen with the initial dose of 1000 mg daily which was increased to 2000 mg after a week and maintained at the same level until the end of the treatment. The average duration of MMF treatment varied depending on the segment of the uvea affected with the inflammation: anterior – 15.5 months, intermediate – 20 months, posterior – 15.3 and 19.5 months in panuveitis (5). MMF treatment regimen implemented at our clinic encompasses an initial dose of 1500–2000 mg daily continued for several months and then it is relatively rapidly reduced in order to achieve c.a. half of the initial dose after a 6-month therapy. After a year of treatment MMF was still administered to 63% of patients, after two years – only 31%, and after 3 years – to 26% of patients.

Dochev et al. reported MMF treatment with the follow-up period of five years, the average MMF treatment duration of 52 months (from 11 to 111 months) with only 33% of patients in whom the drug was discontinued because of achieving the pre-planned effectiveness. The authors did not include information concerning the posology. In the present study the patients were followed up for a shorter period (at least 3 years; average – 51 months) and the average treatment duration was 30 months (from 4 to 106 months), but a therapeutic success was achieved in as many as 59% of patients, so MMF was discontinued. If we comprise the fact that the disease recurred in 2 patients and MMF had to be reintroduced, the percentage falls to 47%. The difference may result from patient characteristics – in the study by Docheva et al. the inflammation affected mainly the intermediate uvea (70% of the participants) and it was demonstrated that MMF was not the most effective
Does the beneficial effect of mycophenolate mofetil persist long-term in the treatment of non-infectious uveitis?

The duration of follow-up in our study is a major advantage of the present study. It was emphasized in the Introduction section that professional literature includes few reports assessing the disease status after 1 year of follow-up. Knowledge gained from the present study may help ophthalmologists in conducting immunosuppressive treatment in patients with non-infectious uveitis. However, the present authors are aware of limitations resulting from retrospective data analysis, as some information may have been skipped in medical records. Moreover, the number of patients with a history that was long enough might also influence the assessment of the results.

References:

1. Jabs D, Rosenbaum J, Yocum D, Holland GN, Jaffe GJ, Louie JS, et al.: Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J of Ophthalmol. 2000; 30(4): 492–513.

2. Teoh S, Hogan A, Dick A, Lee R: Mycophenolate mofetil for the Treatment of Uveitis. Am J Ophthalmol. 2008; 146(5): 752–760.

3. Larkin G, Lightman S: Mycophenolate mofetil. A useful immunosuppressive drug in inflammatory eye disease. Ophthalmology. 1999; 106(2): 370–374.

4. Daniel E, Thome JE, Newcomb CW, Pujari SS, Kaçmaž RO, Levy-Clarke GA, et al.: Mycophenolate mofetil for ocular inflammation. Am J Ophthalmol. 2010; 149(3): 423–432.

5. Siepmann K, Huber M, Stübigner N, Deuter C, Zierhut M: Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol. 2006; 244(7): 788–794.

6. Rodriguez EE, Sakata VM, Cavalcanti DC, Zaghetto JM, Olivalves E, Hirata CE, et al.: Mycophenolate mofetil as an immunomodulator in refractory noninfectious uveitis. Arq Bras Oftalmol. 2016; 79(6): 369–372.

7. Jabs DA, Nussenblatt RB, Rosenbaum JT: Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(5): 509–516.

8. Doycheva D, Zierhut M, Blumenstock G, Stuebigner N, Deuter C: Long-term results of therapy with mycophenolate mofetil in chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2011; 249(8): 1235–1243.

9. Lau CH, Comer M, Lightman S: Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin Exp Ophthalmol. 2003; 31(6): 487–491.

10. Pasadhika S, Kempen J, Suhler E: Azathioprine for Ocular Inflammatory Diseases. Am J Ophthalmol. 2009; 148: 500–509.

The paper was originally received 25.10.2018 (KO-00186-2018)/ Praca wpłynęła do Redakcji 25.10.2018 r. (KO-00186-2018) Accepted for publication 31.03.2019/ Zakwalifikowana do druku 31.03.2019.

Reprint requests to (Adres do korespondencji):
Maja Waszczyk-Łączak, MD
Independent Public University Ophthalmic Hospital,
Warsaw, Poland
03-709 Warsaw, Sierakowskiego 13 Str.
e-mail: majawaszczyk.laczak@gmail.com